Mental HealthVAL-RAS-FRNCT07667686
French Validation of the Recovery Assessment Scale (RAS-FR)
An observational study of Mental Health and Psychiatric Disorders, run by Etablissement Public de Santé Mentale de Metz-Jury at 1 site in France.
Trial summary
The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Mental Health, Psychiatric Disorders
- What is being tested?
- Self-report questionnaires
- How many people
- 260 participants
- Where
- 1 siteFrance
- Study dates
- 29 Jun 2026to Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult psychiatric patients receiving care at EPSM Metz-Jury in inpatient units, day hospital settings, community mental health centers (CMP), or through intensive home-based psychiatric care services (EPSIAD). Participants are French-speaking adults able to complete self-report questionnaires independently or with assistance if needed. Patients under legal protection measures may participate in accordance with applicable regulations.
Who may be able to join
- Adult patient (18 years or older)
- Receiving psychiatric care at EPSM Metz-Jury (inpatient unit, day hospital, community mental health center [CMP], or intensive home-based psychiatric care service [EPSIAD]/post-EPSIAD follow-up)
- Able to understand French
- Able to complete a self-report questionnaire independently or with assistance if needed
- Patients under legal protection measures (guardianship or curatorship) may participate with the agreement of their legal representative, when applicable
Who cannot join
- Major cognitive impairment
- Severe clinical condition preventing questionnaire completion or understanding of French
- Refusal to participate
- Prisoner or person deprived of liberty by judicial or administrative decision
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
EPSM Metz-Jury
Jury, Moselle, 57245
Claire GARIOT, Project Manager, +33387561234, claire.gariot@epsm-metz-jury.fr
About this study
Official title: Cross-Cultural Adaptation, French Validation, and Development of Derived Versions of the Recovery Assessment Scale (RAS) for the Assessment of Subjective Recovery in Mental Health
The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.
Read the detailed description
Recovery in mental health extends beyond symptom reduction and includes hope, self-confidence, autonomy, meaning, and continuity of self. As described by Anthony (1993) and further developed through the CHIME framework, recovery is a deeply personal process involving connectedness, hope, identity, meaning, and empowerment. Although French translations of the Recovery Assessment Scale (RAS) have been used previously, no comprehensive psychometric validation of a French version is currently available for routine use in French-speaking psychiatric settings.
VAL-RAS-FR is a monocentric, prospective, observational study designed to cross-culturally adapt, validate, and develop derived versions of the 41-item Recovery Assessment Scale (RAS) for use in French-speaking mental health settings. The study will enroll 260 adult psychiatric patients receiving care at EPSM Metz-Jury, including patients from inpatient units, day hospital settings, community mental health centers (CMP), and EPSIAD follow-up services. Participants will complete self-report questionnaires including the French version of the RAS (RAS-FR), the WHOQOL-BREF, and complementary questionnaires exploring factors associated with subjective recovery. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability.
The study has three complementary objectives. First, it aims to evaluate the psychometric properties of the French version of the RAS, including validity, internal consistency, dimensional structure, and test-retest reliability. Second, it will explore an existential dimension of recovery through the development of the RAS-FR-EX (Existential Extension), an exploratory extension designed to assess aspects such as continuity of self, reconstruction of meaning, and the experience of existing after psychological crisis. Third, it will support the exploratory development of a shorter version of the scale, the RAS-FR-SF (Short Form), intended to facilitate future clinical use while preserving the core dimensions of subjective recovery.
The study does not involve any modification of usual care, invasive procedures, or additional medical examinations. By combining psychometric validation with exploratory clinical development, VAL-RAS-FR aims to provide a validated French-language measure of subjective recovery, improve the assessment of recovery-oriented outcomes in psychiatric care, and contribute to the development of clinically useful tools for French-speaking mental health services.
- Conditions
- Mental Health, Psychiatric Disorders
- Being tested
- Self-report questionnaires
- Keywords
- subjective recovery, psychiatric care, psychometric validation, Recovery Assessment Scale, patient-reported outcome, mental health, RAS, mental health recovery, quality of life, WHOQOL-BREF, cross-cultural adaptation, recovery-oriented care, existential recovery, RAS-FR, French validation
- Medical subject headings
- Psychological Well-Being, Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-report questionnairesOther
Participants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved.
| Study group | Role | What they receive |
|---|---|---|
| Adult psychiatric patients | Adult psychiatric patients receiving care at EPSM Metz-Jury (inpatient units, day hospital, community mental health centers [CMP], and intensive home-based psychiatric care services [EPSIAD]) who are able to complete self-report questionnaires in French. Receives: Other: Self-report questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability
The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.
Measured: Baseline and 1 month
Secondary outcomes (3)
Correlation between Recovery Assessment Scale - French Version (RAS-FR) and WHOQOL-BREF (World Health Organization Quality of Life - Brief Version) scores
Assessment of convergent validity through correlations between the Recovery Assessment Scale - French Version (RAS-FR) total score and WHOQOL-BREF domain scores in adult psychiatric patients, with particular attention to the psychological and social relationship domains. The RAS-FR total score ranges from 41 to 205, with higher scores indicating a higher level of subjective recovery. WHOQOL-BREF domain scores range from 0 to 100, with higher scores indicating better perceived quality of life. Pearson or Spearman correlation coefficients will be calculated.
Measured: Baseline
Existential dimension of recovery (RAS-FR-EX) composite score
Exploratory assessment of the existential dimension of recovery using six additional items integrated into the French version of the Recovery Assessment Scale (RAS-FR-EX). A composite score ranging from 6 to 30 will be calculated, with higher scores indicating a stronger endorsement of existential recovery processes.
Measured: Baseline
Development of a short-form Recovery Assessment Scale - French Version (RAS-FR-SF)
Exploratory item reduction analyses based on responses to the 41-item Recovery Assessment Scale - French Version (RAS-FR). The objective is to identify a shorter version of the instrument while preserving its psychometric properties and conceptual coverage of subjective recovery.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study start29 Jun 2026
- Primary completionJan 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mental HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 260 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Etablissement Public de Santé Mentale de Metz-Jury
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Hospitalier Régional Metz-Thionville, Groupement Interrégional de Recherche Clinique et d'Innovation
- Responsible party
- Sponsor
- Investigators
- Audrey WILLIG, Psychologist, Principal investigator, Clinical Research Unit (URC), EPSM Metz-Jury
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07667686
- Sponsor's protocol ID
- EPSM-VAL-RAS-FR
- Other IDs
- 2026-A00601-50
- Acronym
- VAL-RAS-FR
- Status last verified
- Aug 2026
- First submitted
- 16 Jun 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be made publicly available. Access to study data may be considered on a case-by-case basis upon request to the sponsor, subject to regulatory requirements, confidentiality obligations, and GDPR compliance.
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-Cultural Adaptation, French Validation, and Development of Derived Versions of the Recovery Assessment Scale (RAS) for the Assessment of Subjective Recovery in Mental Health
- ClinicalTrials.gov ID
- NCT07667686
- Acronym / sponsor ID
- VAL-RAS-FR / EPSM-VAL-RAS-FR
- Conditions
- Mental Health, Psychiatric Disorders
- Keywords
- subjective recovery, psychiatric care, psychometric validation, Recovery Assessment Scale, patient-reported outcome, mental health, RAS, mental health recovery
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 260 participants (estimated)
- Lead sponsor
- Etablissement Public de Santé Mentale de Metz-JuryUniversity, hospital or other
- Collaborators
- Centre Hospitalier Régional Metz-Thionville, Groupement Interrégional de Recherche Clinique et d'Innovation
- Study start
- 29 Jun 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.
Detailed description
Recovery in mental health extends beyond symptom reduction and includes hope, self-confidence, autonomy, meaning, and continuity of self. As described by Anthony (1993) and further developed through the CHIME framework, recovery is a deeply personal process involving connectedness, hope, identity, meaning, and empowerment. Although French translations of the Recovery Assessment Scale (RAS) have been used previously, no comprehensive psychometric validation of a French version is currently available for routine use in French-speaking psychiatric settings.
VAL-RAS-FR is a monocentric, prospective, observational study designed to cross-culturally adapt, validate, and develop derived versions of the 41-item Recovery Assessment Scale (RAS) for use in French-speaking mental health settings. The study will enroll 260 adult psychiatric patients receiving care at EPSM Metz-Jury, including patients from inpatient units, day hospital settings, community mental health centers (CMP), and EPSIAD follow-up services. Participants will complete self-report questionnaires including the French version of the RAS (RAS-FR), the WHOQOL-BREF, and complementary questionnaires exploring factors associated with subjective recovery. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability.
The study has three complementary objectives. First, it aims to evaluate the psychometric properties of the French version of the RAS, including validity, internal consistency, dimensional structure, and test-retest reliability. Second, it will explore an existential dimension of recovery through the development of the RAS-FR-EX (Existential Extension), an exploratory extension designed to assess aspects such as continuity of self, reconstruction of meaning, and the experience of existing after psychological crisis. Third, it will support the exploratory development of a shorter version of the scale, the RAS-FR-SF (Short Form), intended to facilitate future clinical use while preserving the core dimensions of subjective recovery.
The study does not involve any modification of usual care, invasive procedures, or additional medical examinations. By combining psychometric validation with exploratory clinical development, VAL-RAS-FR aims to provide a validated French-language measure of subjective recovery, improve the assessment of recovery-oriented outcomes in psychiatric care, and contribute to the development of clinically useful tools for French-speaking mental health services.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult psychiatric patients | – | Other: Self-report questionnairesAdult psychiatric patients receiving care at EPSM Metz-Jury (inpatient units, day hospital, community mental health centers [CMP], and intensive home-based psychiatric care services [EPSIAD]) who are able to complete self-report questionnaires in French. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult psychiatric patients receiving care at EPSM Metz-Jury in inpatient units, day hospital settings, community mental health centers (CMP), or through intensive home-based psychiatric care services (EPSIAD). Participants are French-speaking adults able to complete self-report questionnaires independently or with assistance if needed. Patients under legal protection measures may participate in accordance with applicable regulations.
Key inclusion criteria (5 listed)
- Adult patient (18 years or older)
- Receiving psychiatric care at EPSM Metz-Jury (inpatient unit, day hospital, community mental health center [CMP], or intensive home-based psychiatric care service [EPSIAD]/post-EPSIAD follow-up)
- Able to understand French
- Able to complete a self-report questionnaire independently or with assistance if needed
- Patients under legal protection measures (guardianship or curatorship) may participate with the agreement of their legal representative, when applicable
Key exclusion criteria (4 listed)
- Major cognitive impairment
- Severe clinical condition preventing questionnaire completion or understanding of French
- Refusal to participate
- Prisoner or person deprived of liberty by judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-report questionnairesParticipants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved. | Other | Adult psychiatric patients |
Primary outcome
Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability
Time frame: Baseline and 1 month
The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.
3 secondary outcomes
Correlation between Recovery Assessment Scale - French Version (RAS-FR) and WHOQOL-BREF (World Health Organization Quality of Life - Brief Version) scores
Time frame: Baseline
Existential dimension of recovery (RAS-FR-EX) composite score
Time frame: Baseline
Development of a short-form Recovery Assessment Scale - French Version (RAS-FR-SF)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be made publicly available. Access to study data may be considered on a case-by-case basis upon request to the sponsor, subject to regulatory requirements, confidentiality obligations, and GDPR compliance.
Related trials for Mental Health
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Audrey WILLIG, Psychologist principal investigator
Clinical Research Unit (URC), EPSM Metz-Jury
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mental Health and Psychiatric Disorders, run by Etablissement Public de Santé Mentale de Metz-Jury at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Audrey WILLIG, Psychologist (+33695082545, audrey.willig@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability (time frame: Baseline and 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.